


REMARKS

Currently claims 1-7 are currently pending in the present application. Claims 1, 2, and 4-6 have been amended to bring them in conformance with U.S. practice. New claim 7 has been added. Support for the new claim may be found on page 8 of the specification. No new matter has been added by way of amendment. Applicants have also amended the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

It is believed that the present applicaiton is now in condition for examination.

Respectfully submitted,



Kathryn L. Coulter
Attorney for Applicant
Registration No. 45,889

Date: *5/30/2006*
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1467
Facsimile: 919-483-7988